Compare Regeneron Pharmaceuticals Inc (REGN) vs Vanguard Information Technology Index Fund ETF (VGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Vanguard Information Technology Index Fund ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $808.33 (market cap $83.43B), while Vanguard Information Technology Index Fund ETF trades at $121. The key difference: Regeneron Pharmaceuticals Inc pays a 0.46% dividend while Vanguard Information Technology Index Fund ETF pays none. Which is the better fit depends on your goals.
| REGN | VGT | |
|---|---|---|
Market Cap | $83.43B | — |
Sector | Health | — |
52-Week High | $852.03 | $125.77 |
52-Week Low | $555.51 | $83.59 |
Enterprise Value | $78.14B | — |
Dividend Yield | 0.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
VGT trades at $121.05, down slightly by 0.18% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF holds a strong position in technology stocks, with recent institutional buying indicating confidence. Key support sits at $119, while resistance is at $122.
The outlook remains positive due to technology sector growth and AI exposure, but risks include high concentration in semiconductor stocks and market volatility. Long-term potential is supported by innovation trends, though investors should monitor sector-specific headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Vanguard Information Technology Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →
